EMA Assessing If Kidney Injury In COVID-19 Patients Is Linked To Remdesivir
While an EU panel is examining reports of acute kidney injury in some COVID-19 patients taking remdesivir, researchers conducting a UK-based study are preparing to update their systematic benefit-risk analysis of the drug as and when more safety data becomes available.
You may also be interested in...
The pharmacovigilance panel at the European Medicines Agency is examining a new safety signal associated with Gilead’s COVID-19 antiviral therapy.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.